Strategy analysis of a case of failure in the treatment of severe pneumonia with ceftazidime avibactam and aztreonam
10.12173/j.issn.1005-0698.202311035
- VernacularTitle:1例头孢他啶阿维巴坦联合氨曲南治疗重症肺炎失败后的药物治疗策略分析
- Author:
Genzhu WANG
1
;
Xiaoying WANG
;
Zhongdong LI
Author Information
1. 国家电网公司北京电力医院/首都医科大学电力教学医院药剂科(北京 100073)
- Keywords:
Carbapenem-resistant Klebsiella pneumonia;
Ceftazidime-avibactam;
Aztreonam;
Colistin sulfate;
Tigecycline;
Anti infection therapy;
Clinical pharmacist
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(3):342-348
- CountryChina
- Language:Chinese
-
Abstract:
To introduce a strategy for a case of severe pneumonia caused by carbapenem-resistant Klebsiella pneumonia,which have failed to treat with tigecycline combined with meropenem,ceftazidime avibactam,and ceftazidime avibactam combined with aztreonam.Clinical pharmacist made anti-infective regimen based on colistin sulfate drip(750 000 units,ivd,q12h,first dose of 1.5 million units)and atomization(250 000 units,q12h)combined with tigecycline(100 mg,ivd,q12h,first dose 200 mg)according to patient's clinical manifestations,renal function,the dynamic changes of infection indicators,metagenomics next-generation sequencing results and the PK/PD characteristics of the anti-bacterial drugs.The anti-infection regimens(intravenous plus aerosolized colistin combined with tigecycline)proposed by the clinical pharmacist were adopted by doctors and the pneumonia was effectively controlled.Clinical pharmacists played an effective role in the clinical healthcare team by tracking frontier of antibacterial drugs,which fully embodied the professional value in optimizing treatment regimens of intractable infections.
